Janus Henderson Group PLC acquired a new position in shares of Promis Neurosciences (NASDAQ:PMN – Free Report) in the 1st quarter, HoldingsChannel reports. The institutional investor acquired 1,292,757 shares of the company’s stock, valued at approximately $16,418,000. Janus Henderson Group PLC owned 0.14% of Promis Neurosciences at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Ally Bridge Group NY LLC increased its holdings in Promis Neurosciences by 66.1% in the first quarter. Ally Bridge Group NY LLC now owns 414,219 shares of the company’s stock valued at $5,261,000 after buying an additional 164,880 shares during the last quarter. Yu Fan purchased a new stake in Promis Neurosciences during the 1st quarter worth about $4,188,000. ADAR1 Capital Management LLC purchased a new stake in Promis Neurosciences during the 1st quarter worth about $1,211,000. Armistice Capital LLC boosted its position in shares of Promis Neurosciences by 39.1% during the 3rd quarter. Armistice Capital LLC now owns 2,974,518 shares of the company’s stock worth $1,264,000 after acquiring an additional 836,622 shares in the last quarter. Finally, Citadel Advisors LLC boosted its position in shares of Promis Neurosciences by 168.1% during the 3rd quarter. Citadel Advisors LLC now owns 170,079 shares of the company’s stock worth $72,000 after acquiring an additional 106,650 shares in the last quarter. Institutional investors and hedge funds own 50.13% of the company’s stock.
Promis Neurosciences Trading Up 3.1%
PMN stock opened at $14.14 on Tuesday. The firm has a 50 day moving average of $12.01 and a 200-day moving average of $13.27. The company has a market cap of $126.81 million, a price-to-earnings ratio of -0.97 and a beta of -0.23. Promis Neurosciences has a 12-month low of $6.27 and a 12-month high of $27.40.
Analyst Ratings Changes
A number of equities analysts recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating on shares of Promis Neurosciences in a report on Wednesday, July 15th. Wall Street Zen upgraded shares of Promis Neurosciences from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 18th. Guggenheim restated a “buy” rating and issued a $69.00 target price (up from $35.00) on shares of Promis Neurosciences in a report on Tuesday, July 28th. Weiss Ratings downgraded shares of Promis Neurosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. Finally, Chardan Capital set a $20.00 target price on shares of Promis Neurosciences and gave the stock a “buy” rating in a research report on Monday, July 27th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $31.50.
View Our Latest Research Report on PMN
Promis Neurosciences Profile
Promis Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.
Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation.
Featured Articles
- Five stocks we like better than Promis Neurosciences
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Want to see what other hedge funds are holding PMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Promis Neurosciences (NASDAQ:PMN – Free Report).
Receive News & Ratings for Promis Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Promis Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
